{"ticker": {"uuid": "b6bc40d7-1601-41b8-9cb4-7e032dbeee24", "symbol": "ZYME", "name": "Zymeworks Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPMVNqZWZ4M1hzSFBtUUFvbEhNcVk0QXNDQmFwTFFsTmxuTHVFOUxvZ2lSaXV1Mng5ZWJWU0w1QmtFa2UtcnBMUDFjN3lxMllFdG1MNG82Z0xldFd6UHFUc1lWR0F1SnVMQ0luZVhPN1RhZEp6eS1oR3hFZDRPVmxSMkh4VGYySFBiX1o4dlhSQzNmTkdkN1dLLVFXb1EyR0M3OU94TDRaTm9GRG91eWM2OTZIRUhnaWVlZS1TNXhYYjFrZmx4?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-18T05:33:28+00:00", "published_display": "18 Jul 2026 05:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdzZ5TmxuSUtlZDBPbjFpT29EUTBnak5xWUpWRFg5ZlNucTBnQy1INGRYT25SbWJ1LUlQZ2dKc2lsYUtrNV9Oa0U1dUs0TnNzX0dzdmdIR3VIX2E1TW9NVkVqWFRZREhyZmUzcEZ4cmZDN0Nkbmh5VFdibWFBMjFERHFwYWQtWXBjTHZhV2tLT2ZsOWtqc2lycUJxNG5pbkdFUTFpOXFMVEpTSlFfZGdrQjNtcHl6SDlK?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-16T10:11:00+00:00", "published_display": "16 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPR3F6WVZsMzdTcWhCdVdtRnpkeXBsYlNRVklhUjFJVjRhSF96c09HV2hVYlFuZV9NcC1Sb3htX3RFX0RPdnRMUG5uMDlIam51QndiTGxock4zbHloVE9rUUM3RmdZU09mSGc2eFJFNFI2Um91Z09CeHd2NGFjY2xwYjl0MHktRU9MVzRxVXhn?oc=5", "source_name": "Market source", "published_at": "2026-07-16T10:00:00+00:00", "published_display": "16 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Won\u2019t Host Q2 Call Amid Proposed Theravance Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQSUhnamJSYnduUDl0V2VTQ0Y0VDFzU256YmdYWERmNmstdmI1T2FnZTB6eTc3YjhqVHNBTEVnZkZaeUZraEc1YjYyMWNUWTVCRnJCTkhzaTRXd2dvSzJYM0NaR2xnRHNnQWFLeUs3aWtvb1I1aDViYXpPSUZDVlhvUUJ5UjBKanU1LWVNSDlxM096U3M5U0JPMms2Zjk2cVJxN1VBWE5EZzk4Q1dOdDRKeWdURVVTaS1lT2hSUmlqdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T10:00:00+00:00", "published_display": "16 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Remains Bullish on Zymeworks (ZYME) \u2013 Here\u2019s Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNcUxTQ2h6TERWS0NqM1NLRkZMXzNoR20tTkxNaEJibXR6OVVZM1VVc3RUUWthVFFwQVh2c09ORzhLc3NvUkVPajhvS2ljamZwNmhGc1dDZTNmRUhEOUxRV05xQ09ycWtkQVM1emxOa3FVaHJoaEk2VVBPVVZOTmoxX1JmOFBjZEVncnpDbjQyUVhyQXZPRV9sV2V1THI1WU1Hd0RwaQ?oc=5", "source_name": "Market source", "published_at": "2026-07-15T08:33:35+00:00", "published_display": "15 Jul 2026 08:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hillsdale Investment Management Inc. Has $8.65 Million Stock Position in Zymeworks Inc. $ZYME", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxNWU5tUTRBbWIxSUhQU0JneGVLUjZwT0FwVmxSVHNwMHM0clRNYUpTd2xIbVlVRmVha0JaMVZ6YVpPZjMwQ09uOUJkV0V3bVhycm9wRlU0bDVZWmxJb21IV0tKMy1jTlFYUjFFS0taeVBXRVAzY2lqNExuelVBV0F2aGpadnk0c3FsZlliLXBGNk9CR19IbEEtVVVEX01jLXNvVEJRdWhJbUtDYjQyUlc1b2dRVXlDM0lmNzkyS0hNUmI1ZjJrZV90YnJYWV9BTThfdnNnR0FDRGxYcnpJdFRVM2xPYw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-14T11:01:51+00:00", "published_display": "14 Jul 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pictet Asset Management Holding SA Has $232,000 Stock Position in Zymeworks Inc. $ZYME", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOb3VVMG5ESWI0bER2LTdpQ01Gd1VyRy1rYUxMc3U0STNxM2hSVFhJdzhxUFlFbllsdURQaFJDaXptMkV4bFRvdW52WGlINy1mX2ZSbVdjQWFxb2otNUxPbFYzcmdqbVlLaFhENU02RDB5aXdJaTJSZzczSnRqeWJaZ0VfY0N6ZV92d2NCR2hJcHAwRE9HZVBrOVJiQjBMX2VvdjJWRlRMSVJ4eUxLaXRrSTdJNU5qcURLVjB3Mk4wbWJXZXA5VTVHLU8zTlRMTGlzZ0NwdkJ4bHZ6WHc?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T08:52:34+00:00", "published_display": "13 Jul 2026 08:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNb0pVUm02aDBDc0Q0azB3NFhtXzlSU0pNSVhFS05TbVZrTThmNkx3TzZKTmxZQ1VIX29DN2VsSE5wNVpLeVJGY3oxYjVwOE5YdFBzNkRnRzh0cU1HVnZIVGt5cGVIYmdHVjZDU0s0eHRraEpIMTRZOTlFSURfMjhITVk2ZWloX3ZjOFVKcjMwaXFYVG43RHJROWFUTnZBTXdYeVJ3Y3FRTzNnaE0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T21:29:45+00:00", "published_display": "06 Jul 2026 21:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arthur Cox advises on pharmaceutical sector acquisition", "summary": "Irish law firm Arthur Cox advised Theravance Biopharma on its acquisition by biotechnology company Zymeworks Inc. The deal, valued at $929 million in equity, will see Theravance Biopharma shareholders receive cash and a contingent value right for future proceeds. This transaction", "url": "https://iclg.com/news/arthur-cox-advises-on-pharmaceutical-sector-acquisition/", "source_name": "ICLG", "published_at": "2026-07-03T21:40:27", "published_display": "03 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZVc5ZElZYWViSHdGRDFOdnZPMExtSzFfam1zQXNaM0d5Um5MVEVud3lyUGpHb1RUVG9wSzlPcE0xdWVhVVJSRGtxUVFxRWJzcFlCZnlMSXFFTHVSY3ZPZldONVNNRkxsMy0zLTU5Rlo3T3hOalJXdVViQS1hRFNPdDVYTzlua1ZLbjlTd1VYck5yM093YmdqRUFxaGNvQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOQTBGVWJhdGtkUnhQSXZuSVJPZEZvSVR3VWVqbFUwdEd2WFBUckFSaDdRVElRZ1pCdGpHV09rOTN0ZjBvdG9VSk1yZ3FpeE5zNmtLcU9OY3NCeGZIeTQ3Y0wxU2hfSGQxOTVwYUk5bzNFNFJkRGp3UmpGdWJnTXNwR1NMRjJzNjdXb3diOURJN25QOUpma1F5RkZnXzJyN0hlOEtnejd4MDI?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Stock Down 3% After Zymeworks Announces Buyout", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/theravance-stock-down-3-zymeworks-125400078.html", "source_name": "Zacks", "published_at": "2026-06-30T12:54:00+00:00", "published_display": "30 Jun 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks agrees to buy Theravance Biopharma for $929m", "summary": "", "url": "https://finance.yahoo.com/m/87f70ae3-bc6a-3369-806b-2658f9e20b11/zymeworks-agrees-to-buy.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-06-30T08:26:59+00:00", "published_display": "30 Jun 2026 08:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks offers US$929-million for COPD drug maker Theravance", "summary": "Zymeworks Inc. is acquiring Dublin-based Theravance Biopharma Inc. for US$929-million in cash, financed partly by Zymeworks' own funds and partly by the Ontario Municipal Employees Retirement System (OMERS). This acquisition marks Zymeworks' entry into the respiratory illness mar", "url": "https://www.theglobeandmail.com/business/article-zymeworks-us929-million-offer-theravance-omers/", "source_name": "The Globe and Mail", "published_at": "2026-06-30T08:09:42", "published_display": "30 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPMlVseE5Cd1dQN0g0Qnh6M3N4LWlHTWlWc1gyZ1R4RHd1X1J0MUM1QlZxNklrZlNzOWptZmFjZmx3TUI1T19rOFBISkdyOHdSVkNmT2ZPSEdTbmxQSlF3di1aQ1hlTnJIa3dnWnJUcG1tTVNuZjdrT1JfSFJ6bnFFRXFMNW40bDZ1dU5rR21wQWhjTmtKNkdVYTdGeU1vdw?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vancouver biotech Zymeworks buying Theravance for US$929M", "summary": "Vancouver-based Zymeworks Inc. is acquiring California's Theravance Biopharma Inc. for US$929 million in cash, a move that diversifies Zymeworks' drug portfolio beyond oncology into respiratory-disease treatments. This acquisition follows Theravance's disappointing clinical trial", "url": "https://www.biv.com/news/technology/vancouver-biotech-zymeworks-buying-theravance-for-us929m-12487280", "source_name": "Business in Vancouver", "published_at": "2026-06-29T19:40:26", "published_display": "29 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks To Buy Theravance Biopharma In $929M Deal \u2013 A Look At What This Deal Means For TBPH Shareholders", "summary": "", "url": "https://finance.yahoo.com/m/65800728-8f43-3d04-94ef-1d11e364578f/zymeworks-to-buy-theravance.html", "source_name": "Stocktwits", "published_at": "2026-06-29T12:44:31+00:00", "published_display": "29 Jun 2026 12:44", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks expands beyond cancer with $929 million Theravance acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOYl96eGp0T2pxeVRxWWpUOVhYNG14TnNURmlxc2d4UW9NcTZsT001b2ttRzBkNXVyaXFYeC1kaFQzRE9Jb1BtWldvZGZJMTJJUk9PTUVmbFFkNFlsdHBHLWp4WXl5Ujh3dUdBSElHangzRFZESHBUeVdjRV9lUS1vSmxWOGFaSGpWYkJ4Y09LaldKSHpvaTJqdHBndHh0ZGJ5SW9kOFBTSGdTc2E2?oc=5", "source_name": "Reuters", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOcWVYMDBCbHJzdE9UeGxTNldWYmJUY2NKeG9GQ05IY21jNXlXMHF6X1NtQmZZRl9ncDQwYk1leGJWY1FHNUEzMXc3Y0thQmRXM05ibzkxNmo1MHltaVI5eXozcDVmb0U4ZmdiVGhwaFZZOU55N2hmamlVUmJJUjg2UEU5NzQ?oc=5", "source_name": "Barron's", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Acquire Theravance Biopharma, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOLVpZOG5UbFVyX1RlSVZCUVRQVTF2UGxfSW5zYVp3YURHWnpSa28zTjYyelcxWEJPVzdzYnExRURvejI3UzZNcVNnTkRIWEdtRTZWWG1OY3E4STFmdGtoX1RQZjJZaTdTeFc1UTRPUnRPQWk2dE9vSWppSFdzSEMxcGVYazBOdkVmSkkzZHhGVjFOZ25wVUZVMmJYa0dIdWt3eXRhV2V0TUswb243SjgyUWM3eEJuQnFL?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (ZYME) Stock Could Be 42.3% Undervalued After Cryo EM Breakthrough", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery", "summary": "Gandeeva Therapeutics and Zymeworks Inc. have announced a collaboration to use Gandeeva's cryo-electron microscopy (cryo-EM) platform to accelerate antibody drug discovery. This partnership aims to leverage cryo-EM technology to gain deeper structural insights into therapeutic an", "url": "https://www.moomoo.com/news/post/71731496/gandeeva-and-zymeworks-use-cryo-em-to-accelerate-antibody-drug", "source_name": "Moomoo", "published_at": "2026-06-20T09:11:35", "published_display": "20 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks partner maps a tiny antibody target at 2.6 \u00c5", "summary": "Gandeeva Therapeutics and Zymeworks have partnered to use cryo-electron microscopy (cryo-EM) to enhance antibody drug discovery. Their collaboration successfully resolved a nine-amino acid epitope of a small, flexible antigen bound to a Zymeworks antibody Fab at 2.6 \u00c5 resolution.", "url": "https://www.stocktitan.net/news/ZYME/gandeeva-and-zymeworks-use-cryo-em-to-accelerate-antibody-drug-wj05yrlv0jyz.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:39:16", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYME - Zymeworks BC Inc Stock Price and Quote", "summary": "This article provides a comprehensive overview of Zymeworks BC Inc. (ZYME) stock, including its latest closing price, financial metrics, analyst ratings, and recent news. It highlights the company's recent acquisition of Theravance Biopharma and details insider trading activity.", "url": "https://finviz.com/stock?t=ZYME", "source_name": "Finviz", "published_at": "2026-05-30T20:09:02", "published_display": "30 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality (ZYME)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPa2J5TUtvZFNLMFIyR0Eza2FvemdORWs2cnd1VU52RlN0MXlHVlJjaE1LbnR5UzlnZVNxQWxYTG1WV1RFRTlybm5DelhmTnBqczNkWC0yb29wbFJCU2RxTHlMN2xpODBtQlItSndnaVhkckhQZkJEX3BPNDJvWUVweC1TcW5ubGdzNWNwdjFPNDR2T0hNckQ4QzhQQ1VqdUJTN0diY0JKVk1tSzUtS0ltQlEwSVdMQ0JjeGp1dk0zWmlPcXA2?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQNllSZks5MDczblBLTVRFRGY1TnBRZWh5V3VVRWtCejF2aHcwanRWSmZ2WVUwZXVQVUV6dl9uZ2RRaC14UmpDZjJsUFlic2lpU2R6VjBGTzNVa0ZGSmY2RGI0bDdZMm1RQS1TMVFQWVlZaGpwbDR2d0Z0dGNoLUpQNlRneXdoX2t2b2tZTjdrekg5c3FrTUFsem5pS2E2MUY2ZkNkSi13?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Inc. (NASDAQ:ZYME) Q1 2026 Earnings Call Transcript", "summary": "Zymeworks Inc. (NASDAQ: ZYME) held its Q1 2026 earnings call, reporting an EPS miss of $-0.59 against an expectation of $-0.1. The company highlighted significant upcoming milestones, including the PDUFA date for zanatumab in first-line GEA, anticipating milestone payments from J", "url": "https://www.insidermonkey.com/blog/zymeworks-inc-nasdaqzyme-q1-2026-earnings-call-transcript-1757073/", "source_name": "Insider Monkey", "published_at": "2026-05-08T12:10:11", "published_display": "08 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (NASDAQ: ZYME) monetizes Ziihera royalties and boosts cash above $400M", "summary": "Zymeworks reported a Q1 2026 net loss of $44.2 million, wider than the previous year, with collaboration revenue falling significantly to $2.4 million due to fewer milestone payments. However, the company boosted its cash, cash equivalents, and marketable securities to over $400 ", "url": "https://www.stocktitan.net/sec-filings/ZYME/10-q-zymeworks-inc-quarterly-earnings-report-dc27e70b8376.html", "source_name": "Stock Titan", "published_at": "2026-05-07T20:09:21", "published_display": "07 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNeDhfOUNZVlpBVXRNSDRTVVZoNnZUUGwxSXRPemxVSTZwYV8yZEZHekxuMW1PSy1NNnl6eVEzeDBERTE2TXJ0c3J1TGI3eFhzRTdWeEdNQXA5WUNBZlJEcE03a1ZWOGR0WkhsdW9VeVFsWXFUNHJYTmhvNDIzcUdpVEVQeFVhUFpSNWNKYlUxMjZ2YzBRRWNuVFl3?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zymeworks makes two interim leaders permanent to steer pipeline and deals", "summary": "Zymeworks has appointed Dr. Adam Schayowitz as Executive VP & Head of R&D and Scott Platshon as Executive VP & Chief Business Officer, making their interim roles permanent. These appointments aim to strengthen the company's R&D, advance its clinical pipeline, and manage its portf", "url": "https://www.stocktitan.net/news/ZYME/zymeworks-announces-additional-leadership-appointments-to-advance-wcsq6sw946l3.html", "source_name": "Stock Titan", "published_at": "2026-04-09T01:09:01", "published_display": "09 Apr 2026 01:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma veteran Kristin Stafford takes CFO post at Zymeworks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNWUluNUpYLThJcUNFRk5nRGV0UkJ3c21UMHpWQ3dmTkt1eGlDdWhRNWdULV9rZHlnLXBLNnRsd29CM1dWWFNWaGY2dnVmQUE2djNXMXE0OGpNUVJzSFNHbmUtbzByb0F1ZzUwNzM4NEI5MUhiTzlMNEVIMXljcGc3dnRNQXJNLVVaQzIxYVdXYXBGNWNCc1pkQ3N5b1JETGdnbFJwM3lMUDVIaHdTNUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "Zymeworks Inc. reported its financial results for the fourth quarter and full year 2025, highlighting a strategic shift towards predictable revenue streams and disciplined capital allocation. The company announced significant progress with its partnered programs, including regula", "url": "https://www.globenewswire.com/news-release/2026/03/02/3247159/0/en/Zymeworks-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html", "source_name": "GlobeNewswire", "published_at": "2026-03-06T20:10:42", "published_display": "06 Mar 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (NASDAQ: ZYME) posts 39% 2025 revenue growth, narrows loss", "summary": "Zymeworks reported a significant financial improvement in 2025, with total revenue rising 39% to $106.0 million and its net loss narrowing by 34% to $81.1 million. The company ended the year with strong liquidity, holding $270.6 million in cash and short-term investments, further", "url": "https://www.stocktitan.net/sec-filings/ZYME/8-k-zymeworks-inc-reports-material-event-66ea60e671c4.html", "source_name": "Stock Titan", "published_at": "2026-03-06T16:39:06", "published_display": "06 Mar 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript", "summary": "Zymeworks Inc. discussed its Q4 2025 earnings and provided updates on its clinical programs and strategic financing. Key highlights include positive Phase III results for zanidatumab in HER2-positive GEA, a new $250 million royalty-backed note financing with Royalty Pharma to fun", "url": "https://www.insidermonkey.com/blog/zymeworks-inc-nasdaqzyme-q4-2025-earnings-call-transcript-1708168/", "source_name": "Insider Monkey", "published_at": "2026-03-03T12:53:12", "published_display": "03 Mar 2026 12:53", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing", "summary": "Zymeworks Inc. has secured a $250 million non-recourse royalty-backed note financing agreement with Royalty Pharma. This deal leverages 30% of future Ziihera (zanidatamab-hrii) royalties from Jazz Pharmaceuticals and BeOne Medicines as collateral, providing Zymeworks with non-dil", "url": "https://www.stocktitan.net/sec-filings/ZYME/8-k-zymeworks-inc-reports-material-event-164352d66fe6.html", "source_name": "Stock Titan", "published_at": "2026-03-02T11:29:20", "published_display": "02 Mar 2026 11:29", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could Zymeworks' blockbuster drug success revive Vancouver biotech scene?", "summary": "Zymeworks Inc. has achieved a significant breakthrough with its lead cancer drug, Zanidatamab, proving effective in Phase 3 trials, potentially generating billions in sales. This success is poised to invigorate Vancouver's biotech sector by creating jobs, attracting investment, a", "url": "https://www.delta-optimist.com/technology/could-zymeworks-blockbuster-drug-success-revive-vancouver-biotech-scene-11612768", "source_name": "Delta Optimist", "published_at": "2025-12-11T23:09:45", "published_display": "11 Dec 2025 23:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz, Zymeworks Bispecific Achieves \u2018Practice-Changing\u2019 Results in Stomach Cancer Study", "summary": "Jazz Pharmaceuticals and Zymeworks' HER2 bispecific antibody Ziihera significantly improved progression-free survival in a Phase III study for gastroesophageal adenocarcinoma, paving the way for a regulatory filing in early 2026. Analysts are optimistic about Ziihera's potential ", "url": "https://www.biospace.com/drug-development/jazz-zymeworks-bispecific-achieves-practice-changing-results-in-stomach-cancer-study", "source_name": "BioSpace", "published_at": "2025-11-18T12:57:57", "published_display": "18 Nov 2025 12:57", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks stock hits four-year high on promising results from digestive cancer trial", "summary": "Zymeworks Inc. stock reached a four-year high following promising results from a late-stage human efficacy trial for its lead drug, Ziihera, in combination with chemotherapy for advanced metastatic gastroesophageal adenocarcinoma (GEA). The drug demonstrated statistically signifi", "url": "https://www.theglobeandmail.com/business/article-zymeworks-stock-four-year-high-digestive-cancer-trial-ziihera/", "source_name": "The Globe and Mail", "published_at": "2025-11-17T21:09:28", "published_display": "17 Nov 2025 21:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer \u2013 What Today\u2019s Breakthrough Means for the Stock and Patients", "summary": "Zymeworks Inc. announced positive topline Phase 3 results for Ziihera (zanidatamab-hrii) in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in progression-free and overall survival. Development partner Jazz Pharmaceuticals plans to file an sBLA in ", "url": "https://ts2.tech/en/zymeworks-zyme-soars-on-positive-phase-3-ziihera-data-in-gastric-cancer-what-todays-breakthrough-means-for-the-stock-and-patients/", "source_name": "ts2.tech", "published_at": "2025-11-17T20:08:58", "published_display": "17 Nov 2025 20:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves cancer drug developed by B.C.'s Zymeworks", "summary": "The FDA has granted accelerated approval for Ziihera, a new drug for biliary tract cancer developed by Zymeworks Inc. in partnership with Jazz Pharmaceuticals. This approval triggers a $25-million milestone payment to Zymeworks and makes them eligible for over $1 billion in total", "url": "https://www.biv.com/news/technology/bc-biotech-zymeworks-gets-fda-approval-for-new-cancer-drug-9847508", "source_name": "Business in Vancouver", "published_at": "2025-10-24T02:02:03", "published_display": "24 Oct 2025 02:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody", "summary": "Jazz Pharmaceuticals and Zymeworks Inc. announced an exclusive licensing agreement for Jazz to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody, in key markets including the U.S., Europe, and Japan. Zymeworks will receive an upfront payment of $50 millio", "url": "https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-zymeworks-announce-exclusive-license-agreement-to-develop-and-commercialize-zanidatamab-a-her2-targeted-bispecific-antibody-301652894.html", "source_name": "PR Newswire", "published_at": "2025-10-24T02:02:03", "published_display": "24 Oct 2025 02:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPMVNqZWZ4M1hzSFBtUUFvbEhNcVk0QXNDQmFwTFFsTmxuTHVFOUxvZ2lSaXV1Mng5ZWJWU0w1QmtFa2UtcnBMUDFjN3lxMllFdG1MNG82Z0xldFd6UHFUc1lWR0F1SnVMQ0luZVhPN1RhZEp6eS1oR3hFZDRPVmxSMkh4VGYySFBiX1o4dlhSQzNmTkdkN1dLLVFXb1EyR0M3OU94TDRaTm9GRG91eWM2OTZIRUhnaWVlZS1TNXhYYjFrZmx4?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-18T05:33:28+00:00", "published_display": "18 Jul 2026 05:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdzZ5TmxuSUtlZDBPbjFpT29EUTBnak5xWUpWRFg5ZlNucTBnQy1INGRYT25SbWJ1LUlQZ2dKc2lsYUtrNV9Oa0U1dUs0TnNzX0dzdmdIR3VIX2E1TW9NVkVqWFRZREhyZmUzcEZ4cmZDN0Nkbmh5VFdibWFBMjFERHFwYWQtWXBjTHZhV2tLT2ZsOWtqc2lycUJxNG5pbkdFUTFpOXFMVEpTSlFfZGdrQjNtcHl6SDlK?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-16T10:11:00+00:00", "published_display": "16 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPR3F6WVZsMzdTcWhCdVdtRnpkeXBsYlNRVklhUjFJVjRhSF96c09HV2hVYlFuZV9NcC1Sb3htX3RFX0RPdnRMUG5uMDlIam51QndiTGxock4zbHloVE9rUUM3RmdZU09mSGc2eFJFNFI2Um91Z09CeHd2NGFjY2xwYjl0MHktRU9MVzRxVXhn?oc=5", "source_name": "Market source", "published_at": "2026-07-16T10:00:00+00:00", "published_display": "16 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Won\u2019t Host Q2 Call Amid Proposed Theravance Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQSUhnamJSYnduUDl0V2VTQ0Y0VDFzU256YmdYWERmNmstdmI1T2FnZTB6eTc3YjhqVHNBTEVnZkZaeUZraEc1YjYyMWNUWTVCRnJCTkhzaTRXd2dvSzJYM0NaR2xnRHNnQWFLeUs3aWtvb1I1aDViYXpPSUZDVlhvUUJ5UjBKanU1LWVNSDlxM096U3M5U0JPMms2Zjk2cVJxN1VBWE5EZzk4Q1dOdDRKeWdURVVTaS1lT2hSUmlqdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T10:00:00+00:00", "published_display": "16 Jul 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Remains Bullish on Zymeworks (ZYME) \u2013 Here\u2019s Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNcUxTQ2h6TERWS0NqM1NLRkZMXzNoR20tTkxNaEJibXR6OVVZM1VVc3RUUWthVFFwQVh2c09ORzhLc3NvUkVPajhvS2ljamZwNmhGc1dDZTNmRUhEOUxRV05xQ09ycWtkQVM1emxOa3FVaHJoaEk2VVBPVVZOTmoxX1JmOFBjZEVncnpDbjQyUVhyQXZPRV9sV2V1THI1WU1Hd0RwaQ?oc=5", "source_name": "Market source", "published_at": "2026-07-15T08:33:35+00:00", "published_display": "15 Jul 2026 08:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hillsdale Investment Management Inc. Has $8.65 Million Stock Position in Zymeworks Inc. $ZYME", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxNWU5tUTRBbWIxSUhQU0JneGVLUjZwT0FwVmxSVHNwMHM0clRNYUpTd2xIbVlVRmVha0JaMVZ6YVpPZjMwQ09uOUJkV0V3bVhycm9wRlU0bDVZWmxJb21IV0tKMy1jTlFYUjFFS0taeVBXRVAzY2lqNExuelVBV0F2aGpadnk0c3FsZlliLXBGNk9CR19IbEEtVVVEX01jLXNvVEJRdWhJbUtDYjQyUlc1b2dRVXlDM0lmNzkyS0hNUmI1ZjJrZV90YnJYWV9BTThfdnNnR0FDRGxYcnpJdFRVM2xPYw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-14T11:01:51+00:00", "published_display": "14 Jul 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pictet Asset Management Holding SA Has $232,000 Stock Position in Zymeworks Inc. $ZYME", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOb3VVMG5ESWI0bER2LTdpQ01Gd1VyRy1rYUxMc3U0STNxM2hSVFhJdzhxUFlFbllsdURQaFJDaXptMkV4bFRvdW52WGlINy1mX2ZSbVdjQWFxb2otNUxPbFYzcmdqbVlLaFhENU02RDB5aXdJaTJSZzczSnRqeWJaZ0VfY0N6ZV92d2NCR2hJcHAwRE9HZVBrOVJiQjBMX2VvdjJWRlRMSVJ4eUxLaXRrSTdJNU5qcURLVjB3Mk4wbWJXZXA5VTVHLU8zTlRMTGlzZ0NwdkJ4bHZ6WHc?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T08:52:34+00:00", "published_display": "13 Jul 2026 08:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNb0pVUm02aDBDc0Q0azB3NFhtXzlSU0pNSVhFS05TbVZrTThmNkx3TzZKTmxZQ1VIX29DN2VsSE5wNVpLeVJGY3oxYjVwOE5YdFBzNkRnRzh0cU1HVnZIVGt5cGVIYmdHVjZDU0s0eHRraEpIMTRZOTlFSURfMjhITVk2ZWloX3ZjOFVKcjMwaXFYVG43RHJROWFUTnZBTXdYeVJ3Y3FRTzNnaE0?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T21:29:45+00:00", "published_display": "06 Jul 2026 21:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arthur Cox advises on pharmaceutical sector acquisition", "summary": "Irish law firm Arthur Cox advised Theravance Biopharma on its acquisition by biotechnology company Zymeworks Inc. The deal, valued at $929 million in equity, will see Theravance Biopharma shareholders receive cash and a contingent value right for future proceeds. This transaction", "url": "https://iclg.com/news/arthur-cox-advises-on-pharmaceutical-sector-acquisition/", "source_name": "ICLG", "published_at": "2026-07-03T21:40:27", "published_display": "03 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZVc5ZElZYWViSHdGRDFOdnZPMExtSzFfam1zQXNaM0d5Um5MVEVud3lyUGpHb1RUVG9wSzlPcE0xdWVhVVJSRGtxUVFxRWJzcFlCZnlMSXFFTHVSY3ZPZldONVNNRkxsMy0zLTU5Rlo3T3hOalJXdVViQS1hRFNPdDVYTzlua1ZLbjlTd1VYck5yM093YmdqRUFxaGNvQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOQTBGVWJhdGtkUnhQSXZuSVJPZEZvSVR3VWVqbFUwdEd2WFBUckFSaDdRVElRZ1pCdGpHV09rOTN0ZjBvdG9VSk1yZ3FpeE5zNmtLcU9OY3NCeGZIeTQ3Y0wxU2hfSGQxOTVwYUk5bzNFNFJkRGp3UmpGdWJnTXNwR1NMRjJzNjdXb3diOURJN25QOUpma1F5RkZnXzJyN0hlOEtnejd4MDI?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Theravance Stock Down 3% After Zymeworks Announces Buyout", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/theravance-stock-down-3-zymeworks-125400078.html", "source_name": "Zacks", "published_at": "2026-06-30T12:54:00+00:00", "published_display": "30 Jun 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks agrees to buy Theravance Biopharma for $929m", "summary": "", "url": "https://finance.yahoo.com/m/87f70ae3-bc6a-3369-806b-2658f9e20b11/zymeworks-agrees-to-buy.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-06-30T08:26:59+00:00", "published_display": "30 Jun 2026 08:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks offers US$929-million for COPD drug maker Theravance", "summary": "Zymeworks Inc. is acquiring Dublin-based Theravance Biopharma Inc. for US$929-million in cash, financed partly by Zymeworks' own funds and partly by the Ontario Municipal Employees Retirement System (OMERS). This acquisition marks Zymeworks' entry into the respiratory illness mar", "url": "https://www.theglobeandmail.com/business/article-zymeworks-us929-million-offer-theravance-omers/", "source_name": "The Globe and Mail", "published_at": "2026-06-30T08:09:42", "published_display": "30 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPMlVseE5Cd1dQN0g0Qnh6M3N4LWlHTWlWc1gyZ1R4RHd1X1J0MUM1QlZxNklrZlNzOWptZmFjZmx3TUI1T19rOFBISkdyOHdSVkNmT2ZPSEdTbmxQSlF3di1aQ1hlTnJIa3dnWnJUcG1tTVNuZjdrT1JfSFJ6bnFFRXFMNW40bDZ1dU5rR21wQWhjTmtKNkdVYTdGeU1vdw?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vancouver biotech Zymeworks buying Theravance for US$929M", "summary": "Vancouver-based Zymeworks Inc. is acquiring California's Theravance Biopharma Inc. for US$929 million in cash, a move that diversifies Zymeworks' drug portfolio beyond oncology into respiratory-disease treatments. This acquisition follows Theravance's disappointing clinical trial", "url": "https://www.biv.com/news/technology/vancouver-biotech-zymeworks-buying-theravance-for-us929m-12487280", "source_name": "Business in Vancouver", "published_at": "2026-06-29T19:40:26", "published_display": "29 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks To Buy Theravance Biopharma In $929M Deal \u2013 A Look At What This Deal Means For TBPH Shareholders", "summary": "", "url": "https://finance.yahoo.com/m/65800728-8f43-3d04-94ef-1d11e364578f/zymeworks-to-buy-theravance.html", "source_name": "Stocktwits", "published_at": "2026-06-29T12:44:31+00:00", "published_display": "29 Jun 2026 12:44", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks expands beyond cancer with $929 million Theravance acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOYl96eGp0T2pxeVRxWWpUOVhYNG14TnNURmlxc2d4UW9NcTZsT001b2ttRzBkNXVyaXFYeC1kaFQzRE9Jb1BtWldvZGZJMTJJUk9PTUVmbFFkNFlsdHBHLWp4WXl5Ujh3dUdBSElHangzRFZESHBUeVdjRV9lUS1vSmxWOGFaSGpWYkJ4Y09LaldKSHpvaTJqdHBndHh0ZGJ5SW9kOFBTSGdTc2E2?oc=5", "source_name": "Reuters", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOcWVYMDBCbHJzdE9UeGxTNldWYmJUY2NKeG9GQ05IY21jNXlXMHF6X1NtQmZZRl9ncDQwYk1leGJWY1FHNUEzMXc3Y0thQmRXM05ibzkxNmo1MHltaVI5eXozcDVmb0U4ZmdiVGhwaFZZOU55N2hmamlVUmJJUjg2UEU5NzQ?oc=5", "source_name": "Barron's", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks to Acquire Theravance Biopharma, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOLVpZOG5UbFVyX1RlSVZCUVRQVTF2UGxfSW5zYVp3YURHWnpSa28zTjYyelcxWEJPVzdzYnExRURvejI3UzZNcVNnTkRIWEdtRTZWWG1OY3E4STFmdGtoX1RQZjJZaTdTeFc1UTRPUnRPQWk2dE9vSWppSFdzSEMxcGVYazBOdkVmSkkzZHhGVjFOZ25wVUZVMmJYa0dIdWt3eXRhV2V0TUswb243SjgyUWM3eEJuQnFL?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (ZYME) Stock Could Be 42.3% Undervalued After Cryo EM Breakthrough", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery", "summary": "Gandeeva Therapeutics and Zymeworks Inc. have announced a collaboration to use Gandeeva's cryo-electron microscopy (cryo-EM) platform to accelerate antibody drug discovery. This partnership aims to leverage cryo-EM technology to gain deeper structural insights into therapeutic an", "url": "https://www.moomoo.com/news/post/71731496/gandeeva-and-zymeworks-use-cryo-em-to-accelerate-antibody-drug", "source_name": "Moomoo", "published_at": "2026-06-20T09:11:35", "published_display": "20 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks partner maps a tiny antibody target at 2.6 \u00c5", "summary": "Gandeeva Therapeutics and Zymeworks have partnered to use cryo-electron microscopy (cryo-EM) to enhance antibody drug discovery. Their collaboration successfully resolved a nine-amino acid epitope of a small, flexible antigen bound to a Zymeworks antibody Fab at 2.6 \u00c5 resolution.", "url": "https://www.stocktitan.net/news/ZYME/gandeeva-and-zymeworks-use-cryo-em-to-accelerate-antibody-drug-wj05yrlv0jyz.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:39:16", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYME - Zymeworks BC Inc Stock Price and Quote", "summary": "This article provides a comprehensive overview of Zymeworks BC Inc. (ZYME) stock, including its latest closing price, financial metrics, analyst ratings, and recent news. It highlights the company's recent acquisition of Theravance Biopharma and details insider trading activity.", "url": "https://finviz.com/stock?t=ZYME", "source_name": "Finviz", "published_at": "2026-05-30T20:09:02", "published_display": "30 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality (ZYME)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPa2J5TUtvZFNLMFIyR0Eza2FvemdORWs2cnd1VU52RlN0MXlHVlJjaE1LbnR5UzlnZVNxQWxYTG1WV1RFRTlybm5DelhmTnBqczNkWC0yb29wbFJCU2RxTHlMN2xpODBtQlItSndnaVhkckhQZkJEX3BPNDJvWUVweC1TcW5ubGdzNWNwdjFPNDR2T0hNckQ4QzhQQ1VqdUJTN0diY0JKVk1tSzUtS0ltQlEwSVdMQ0JjeGp1dk0zWmlPcXA2?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQNllSZks5MDczblBLTVRFRGY1TnBRZWh5V3VVRWtCejF2aHcwanRWSmZ2WVUwZXVQVUV6dl9uZ2RRaC14UmpDZjJsUFlic2lpU2R6VjBGTzNVa0ZGSmY2RGI0bDdZMm1RQS1TMVFQWVlZaGpwbDR2d0Z0dGNoLUpQNlRneXdoX2t2b2tZTjdrekg5c3FrTUFsem5pS2E2MUY2ZkNkSi13?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Inc. (NASDAQ:ZYME) Q1 2026 Earnings Call Transcript", "summary": "Zymeworks Inc. (NASDAQ: ZYME) held its Q1 2026 earnings call, reporting an EPS miss of $-0.59 against an expectation of $-0.1. The company highlighted significant upcoming milestones, including the PDUFA date for zanatumab in first-line GEA, anticipating milestone payments from J", "url": "https://www.insidermonkey.com/blog/zymeworks-inc-nasdaqzyme-q1-2026-earnings-call-transcript-1757073/", "source_name": "Insider Monkey", "published_at": "2026-05-08T12:10:11", "published_display": "08 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (NASDAQ: ZYME) monetizes Ziihera royalties and boosts cash above $400M", "summary": "Zymeworks reported a Q1 2026 net loss of $44.2 million, wider than the previous year, with collaboration revenue falling significantly to $2.4 million due to fewer milestone payments. However, the company boosted its cash, cash equivalents, and marketable securities to over $400 ", "url": "https://www.stocktitan.net/sec-filings/ZYME/10-q-zymeworks-inc-quarterly-earnings-report-dc27e70b8376.html", "source_name": "Stock Titan", "published_at": "2026-05-07T20:09:21", "published_display": "07 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNeDhfOUNZVlpBVXRNSDRTVVZoNnZUUGwxSXRPemxVSTZwYV8yZEZHekxuMW1PSy1NNnl6eVEzeDBERTE2TXJ0c3J1TGI3eFhzRTdWeEdNQXA5WUNBZlJEcE03a1ZWOGR0WkhsdW9VeVFsWXFUNHJYTmhvNDIzcUdpVEVQeFVhUFpSNWNKYlUxMjZ2YzBRRWNuVFl3?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks makes two interim leaders permanent to steer pipeline and deals", "summary": "Zymeworks has appointed Dr. Adam Schayowitz as Executive VP & Head of R&D and Scott Platshon as Executive VP & Chief Business Officer, making their interim roles permanent. These appointments aim to strengthen the company's R&D, advance its clinical pipeline, and manage its portf", "url": "https://www.stocktitan.net/news/ZYME/zymeworks-announces-additional-leadership-appointments-to-advance-wcsq6sw946l3.html", "source_name": "Stock Titan", "published_at": "2026-04-09T01:09:01", "published_display": "09 Apr 2026 01:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma veteran Kristin Stafford takes CFO post at Zymeworks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNWUluNUpYLThJcUNFRk5nRGV0UkJ3c21UMHpWQ3dmTkt1eGlDdWhRNWdULV9rZHlnLXBLNnRsd29CM1dWWFNWaGY2dnVmQUE2djNXMXE0OGpNUVJzSFNHbmUtbzByb0F1ZzUwNzM4NEI5MUhiTzlMNEVIMXljcGc3dnRNQXJNLVVaQzIxYVdXYXBGNWNCc1pkQ3N5b1JETGdnbFJwM3lMUDVIaHdTNUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "Zymeworks Inc. reported its financial results for the fourth quarter and full year 2025, highlighting a strategic shift towards predictable revenue streams and disciplined capital allocation. The company announced significant progress with its partnered programs, including regula", "url": "https://www.globenewswire.com/news-release/2026/03/02/3247159/0/en/Zymeworks-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html", "source_name": "GlobeNewswire", "published_at": "2026-03-06T20:10:42", "published_display": "06 Mar 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (NASDAQ: ZYME) posts 39% 2025 revenue growth, narrows loss", "summary": "Zymeworks reported a significant financial improvement in 2025, with total revenue rising 39% to $106.0 million and its net loss narrowing by 34% to $81.1 million. The company ended the year with strong liquidity, holding $270.6 million in cash and short-term investments, further", "url": "https://www.stocktitan.net/sec-filings/ZYME/8-k-zymeworks-inc-reports-material-event-66ea60e671c4.html", "source_name": "Stock Titan", "published_at": "2026-03-06T16:39:06", "published_display": "06 Mar 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript", "summary": "Zymeworks Inc. discussed its Q4 2025 earnings and provided updates on its clinical programs and strategic financing. Key highlights include positive Phase III results for zanidatumab in HER2-positive GEA, a new $250 million royalty-backed note financing with Royalty Pharma to fun", "url": "https://www.insidermonkey.com/blog/zymeworks-inc-nasdaqzyme-q4-2025-earnings-call-transcript-1708168/", "source_name": "Insider Monkey", "published_at": "2026-03-03T12:53:12", "published_display": "03 Mar 2026 12:53", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing", "summary": "Zymeworks Inc. has secured a $250 million non-recourse royalty-backed note financing agreement with Royalty Pharma. This deal leverages 30% of future Ziihera (zanidatamab-hrii) royalties from Jazz Pharmaceuticals and BeOne Medicines as collateral, providing Zymeworks with non-dil", "url": "https://www.stocktitan.net/sec-filings/ZYME/8-k-zymeworks-inc-reports-material-event-164352d66fe6.html", "source_name": "Stock Titan", "published_at": "2026-03-02T11:29:20", "published_display": "02 Mar 2026 11:29", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could Zymeworks' blockbuster drug success revive Vancouver biotech scene?", "summary": "Zymeworks Inc. has achieved a significant breakthrough with its lead cancer drug, Zanidatamab, proving effective in Phase 3 trials, potentially generating billions in sales. This success is poised to invigorate Vancouver's biotech sector by creating jobs, attracting investment, a", "url": "https://www.delta-optimist.com/technology/could-zymeworks-blockbuster-drug-success-revive-vancouver-biotech-scene-11612768", "source_name": "Delta Optimist", "published_at": "2025-12-11T23:09:45", "published_display": "11 Dec 2025 23:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz, Zymeworks Bispecific Achieves \u2018Practice-Changing\u2019 Results in Stomach Cancer Study", "summary": "Jazz Pharmaceuticals and Zymeworks' HER2 bispecific antibody Ziihera significantly improved progression-free survival in a Phase III study for gastroesophageal adenocarcinoma, paving the way for a regulatory filing in early 2026. Analysts are optimistic about Ziihera's potential ", "url": "https://www.biospace.com/drug-development/jazz-zymeworks-bispecific-achieves-practice-changing-results-in-stomach-cancer-study", "source_name": "BioSpace", "published_at": "2025-11-18T12:57:57", "published_display": "18 Nov 2025 12:57", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks stock hits four-year high on promising results from digestive cancer trial", "summary": "Zymeworks Inc. stock reached a four-year high following promising results from a late-stage human efficacy trial for its lead drug, Ziihera, in combination with chemotherapy for advanced metastatic gastroesophageal adenocarcinoma (GEA). The drug demonstrated statistically signifi", "url": "https://www.theglobeandmail.com/business/article-zymeworks-stock-four-year-high-digestive-cancer-trial-ziihera/", "source_name": "The Globe and Mail", "published_at": "2025-11-17T21:09:28", "published_display": "17 Nov 2025 21:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer \u2013 What Today\u2019s Breakthrough Means for the Stock and Patients", "summary": "Zymeworks Inc. announced positive topline Phase 3 results for Ziihera (zanidatamab-hrii) in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in progression-free and overall survival. Development partner Jazz Pharmaceuticals plans to file an sBLA in ", "url": "https://ts2.tech/en/zymeworks-zyme-soars-on-positive-phase-3-ziihera-data-in-gastric-cancer-what-todays-breakthrough-means-for-the-stock-and-patients/", "source_name": "ts2.tech", "published_at": "2025-11-17T20:08:58", "published_display": "17 Nov 2025 20:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves cancer drug developed by B.C.'s Zymeworks", "summary": "The FDA has granted accelerated approval for Ziihera, a new drug for biliary tract cancer developed by Zymeworks Inc. in partnership with Jazz Pharmaceuticals. This approval triggers a $25-million milestone payment to Zymeworks and makes them eligible for over $1 billion in total", "url": "https://www.biv.com/news/technology/bc-biotech-zymeworks-gets-fda-approval-for-new-cancer-drug-9847508", "source_name": "Business in Vancouver", "published_at": "2025-10-24T02:02:03", "published_display": "24 Oct 2025 02:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody", "summary": "Jazz Pharmaceuticals and Zymeworks Inc. announced an exclusive licensing agreement for Jazz to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody, in key markets including the U.S., Europe, and Japan. Zymeworks will receive an upfront payment of $50 millio", "url": "https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-zymeworks-announce-exclusive-license-agreement-to-develop-and-commercialize-zanidatamab-a-her2-targeted-bispecific-antibody-301652894.html", "source_name": "PR Newswire", "published_at": "2025-10-24T02:02:03", "published_display": "24 Oct 2025 02:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 61, "sentiment_summary": {"positive": 28, "negative": 4, "neutral": 29, "score": 58, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 14.75, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 13.69, "count": 26}, {"event": "deals", "label": "Deals and strategy", "weight": 5.85, "count": 10}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 28, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 24.19, "latest_week": "2026-07-17", "one_week_move": -6.5, "four_week_move": 4.5, "twelve_week_move": -13.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.706418, "market_dynamics_buy_signal": false, "relative_strength": 0.079074, "fair_value_gap": 66.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.8038, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.5% over one week, +4.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 8}, {"label": "Barron's", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Quiver Quantitative", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 26}, {"label": "Market update", "count": 23}, {"label": "Deals and strategy", "count": 10}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "8", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.5% over one week, +4.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long"}], "updated_at": "2026-07-18T13:29:37.547501+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}